Acceleron Pharma

INVESTORS MEDIA. Oral Presentation Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplas. Our discovery platform is an exceptionally rich source of novel protein therapies to treat patients with life-threatening and debilitating conditions.

OVERVIEW

The web site acceleronpharma.com currently has an average traffic classification of zero (the lower the superior). We have parsed thirteen pages inside the site acceleronpharma.com and found one hundred and five websites associating themselves with acceleronpharma.com. There is two contacts and locations for acceleronpharma.com to help you reach them. There is two public web platforms belong to this website. The web site acceleronpharma.com has been on the internet for one thousand and sixty-four weeks, twenty-three days, one hour, and forty-four minutes.
Pages Parsed
13
Links to this site
105
Contacts
2
Addresses
2
Social Links
2
Online Since
Dec 2003

ACCELERONPHARMA.COM TRAFFIC

The web site acceleronpharma.com has seen variant levels of traffic all over the year.
Traffic for acceleronpharma.com

Date Range

1 week
1 month
3 months
This Year
Last Year
All time
Traffic ranking (by month) for acceleronpharma.com

Date Range

All time
This Year
Last Year
Traffic ranking by day of the week for acceleronpharma.com

Date Range

All time
This Year
Last Year
Last Month

ACCELERONPHARMA.COM HISTORY

The web site acceleronpharma.com was created on December 21, 2003. This domain was last updated on September 21, 2007. It will go back on the market on December 21, 2014. It is now one thousand and sixty-four weeks, twenty-three days, one hour, and forty-four minutes young.
REGISTERED
December
2003
UPDATED
September
2007
EXPIRED
December
2014

AGE

20
YEARS
4
MONTHS
22
DAYS

LINKS TO ACCELERONPHARMA.COM

Home Adimab

How to Work with Adimab. Adimab Announces New Bispecific Antibody Collaboration with Sanofi. Adimab Announces Expansion of its Collaboration with GSK for the Discovery of Bispecific Antibodies.

Alkermes plc A Global Biopharmaceutical Company

Alkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease. Alkermes plc Reports First Quarter 2015 Financial Results Read More. Alkermes to Host Conference Call to Discuss First Quarter 2015 Financial Results Read More.

Venture Capital from ATV - Advanced Technology Ventures

View our full video library. Our CEOs share their perspectives on what it takes to be a successful entrepreneur. Mike Peronto, CEO of WildTangent. John Knopf, CEO of Acceleron Pharma.

Home - Avalon Ventures

Since day one of their investment, Avalon has provided their time, energy and resources to help us on our mission of becoming the defacto data layer for all web and mobile applications. Mdash; Derek Schoettle, CEO of Cloudant.

BiotechPress, lactualité des biotechnologies par les étudiants de SupBiotech

Se loger, se restaurer.

Biotech Industry, Biotech News, Biotechnology Articles FierceBiotech

Use a to require a term in results and - to exclude terms. Celgene drops option to buy Abide, bags preclinical drug. Edge plans job cuts as phase 3 brain-bleed fail routs stock.

Flagship Ventures creates and finances companies in therapeutics, medical technologies and sustainability.

Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update. Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress. BIND Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update. Acceleron Pharma Reports Second Quarter 2015 Financial and Operational Results. People in biopharma in 2015.

WHAT DOES ACCELERONPHARMA.COM LOOK LIKE?

Desktop Screenshot of acceleronpharma.com Mobile Screenshot of acceleronpharma.com Tablet Screenshot of acceleronpharma.com

CONTACTS

Acceleron Pharma

24 Emily Street

Cambridge, MA, 02139

US

Acceleron Pharma

Acceleron Pharma

24 Emily Street

Cambridge, MA, 02139

US

ACCELERONPHARMA.COM SERVER

Our crawlers detected that a lone root page on acceleronpharma.com took four thousand nine hundred and thirty milliseconds to come up. We could not find a SSL certificate, so we consider this site not secure.
Load time
4.93 sec
SSL
NOT SECURE
IP
64.90.51.226

NAME SERVERS

ns1.p30.dynect.net
ns2.p30.dynect.net
ns3.p30.dynect.net
ns4.p30.dynect.net

SERVER SOFTWARE AND ENCODING

We revealed that this website is employing the Apache operating system.

SITE TITLE

Acceleron Pharma

DESCRIPTION

INVESTORS MEDIA. Oral Presentation Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplas. Our discovery platform is an exceptionally rich source of novel protein therapies to treat patients with life-threatening and debilitating conditions.

PARSED CONTENT

The web site acceleronpharma.com states the following, "Oral Presentation Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplas." I noticed that the website also stated " Our discovery platform is an exceptionally rich source of novel protein therapies to treat patients with life-threatening and debilitating conditions."

SEE SIMILAR WEBSITES

Acceleron Soybean Corn Cotton Seed Treatment Products

Turn off more accessible mode. Locate your Rep and Dealer. Seed Treatment Products can help improve plant health through disease-fighting protection, insect protection and improved early season vigor. Seed Treatment Products are the only seed treatments designed to help maximize performance potential in Genuity.

Acceleroto, Inc.

Yosemite star trail backgrounds for your iPhone, iPad or Mac. Space backgrounds for your iOS 7 iPhone 5S, 5C or 5. Site designed by We Heart Games.

business growth experts

Low Cost, High Return. We ready your organization for accelerated growth by ensuring the right strategies and funding are in place. We help businesses overcome periods of challenge, restoring progress and growth. Accelerus are business growth experts with a distinctive hands-on approach that assures commercial performance improvement. FIVE KEY TRENDS FOR MANUFACTURING. Accelerus has identified five key trends which will impact on the manufacturing sector over.

Strength and Conditioning Software Accelerware

Everything You Need In One Cloud Software. Everything You need in One Cloud Software. That is what you do. Schedule clients, staff and facilities using the Calendar. Keep an inventory of all your equipment, supplements, etc.

The best managed print service managed print consultants in NYC metro. Accelery MPS

We offer a risk-free business model that quantifies your savings before you sign a contract. There is no fee for the initial analysis of your existing printer fleet. We use this assessment to establish a baseline operating cost and identify results you can expect with our managed print solution. Then we go to work to deliver what we promise. Identifying green opportunities gets top priority with Accelery MPS. We serve as your experts on device and service carbon footp.